Levofloxacin hemihydrate.
Each Film Coated Tablet contains Levofloxacin (Hemihydrate), USP 500 mg.
Pharmacology: Pharmacodynamics/Pharmacokinetics: Levofloxacin is rapidly absorbed almost completely absorbed following oral use peak plasma concentration within 1 to 2 hours. It is widely distributed into body tissue including the bronchial mucosa and lungs, but penetration into the CSF is relatively poor. Levofloxacin is approximately 30 to 40% bound to plasma proteins.
It is only metabolized to a small degree to inactive metabolism. The elimination half-life of levofloxacin is 6 to 8 hours. Although this may be prolonged in patients with renal impairment.
Levofloxacin is excreted largely unchanged primarily in the urine. It is not removed by haemodialysis or peritoneal dialysis.
Levofloxacin is indicated for the treatment of susceptible infection such as urinary tract infection, infected bites and sting, bone and joints infections brucellosis, gastroenteritis, diarrhea, meningitis, lower respiratory tract infection, skin and urinary tract infection.
It is given by mouth for the treatment of susceptible infection in a usual dose of 250 or 500 mg once or twice daily for 7-14 days or as prescribed by physician.
Levofloxacin is concentrated in person with history of hypersensitivity of levofloxacin, quinolone anti-microbial agents, or any other component of this product.
Levofloxacin should be used with caution in patients with epilepsy or has a history of CNS disorders.
Levofloxacin and related fluoroquinolone have been shown to cause degenerative changes in weight-bearing joints of young animals and should not be used in children, adolescents, pregnant woman or breast-feeding mothers should be avoided in medicine.
Levofloxacin is a category C pregnancy drug. Talk to the doctor if pregnant or planning to become pregnant. This drug should be used only if the potential benefit justifies the potential risk to the fetus. Levofloxacin passes into breast milk and may cause side effect in a child who is breast-fed.
The range of adverse effects associated with fluoroquinolone antibacterial agents is broadly similar to quinolones such as nalidixic acid. They most often involved the gastrointestinal tract, central nervous system or skin. Gastrointestinal disturbance include nausea, vomiting, diarrhea, abdominal pain and dyspepsia and are the most frequent adverse effects. Pseudomembranous colitis has been reported rarely. Headache, dizziness and restlessness are most common effect on the CNS.
Others include tremor, drowsiness, insomnia, nightmares and visual disturbance and more rarely, hallucinations, psychotic reactions, depression and convulsion. Peripheral neuropathy has occurred occasionally.
Fluoroquinolone are known to inhibit hepatic drug metabolism and may interfere with the clearance of drugs, such as theophylline that are metabolized by the liver. Cations like aluminum, magnesium or iron reduce the absorption of fluoroquinolones when given concomitantly.
Store at temperatures not exceeding 30°C.
J01MA12 - levofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Teravox tab 500 mg
30's (P1,654/pack)
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
